Stocks

One thing we could say about the analysts on Nektar Therapeutics (NASDAQ:NKTR) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts …

F5, Inc. (NASDAQ:FFIV) just reported healthy earnings but the stock price didn't move much. Our analysis suggests that investors might be missing some promising details. We check all companies for important risks. See what we found for F5 in our free report.NasdaqGS:FFIV Earnings and …

HR outsourcing provider Insperity (NYSE:NSP) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 3.4% year on year to $1.86 billion. Its non-GAAP profit of $1.56 per share was 23% below analysts’ consensus estimates. Is now the time to buy NSP? Find …

LiveRamp Holdings, Inc. (NYSE:RAMP) shareholders should be happy to see the share price up 17% in the last month. But if you look at the last five years the returns have not been good. In fact, the share price is down 25%, which falls …

Key Points These players share a product, one set to generate significant growth over time. Both of these stocks offer investors a bargain at their prices today. 10 stocks we like better than CRISPR Therapeutics › It's very tempting to pile into the stocks …

For Immediate Release Chicago, IL – May 13, 2025 – The stocks in this week’s article are Avino Silver & Gold Mines Ltd. ASM, Pagaya Technologies Ltd. PGY, EverQuote, Inc. EVER and Sezzle Inc. SEZL. 4 Top-Ranked Liquid Stocks to Bet on for Boosting …

Key Points Tesla's historical growth trajectory was unbelievable, but the automaker is now struggling. Prospective investors today must consider how bullish they are about Musk's robotaxi vision. Although it's now down 38% from its peak, the market continues to price ambitious expectations into Tesla …